Ferroptosis Inhibition Therapy is a neuroprotective strategy targeting the iron-dependent lipid peroxidation pathway that drives neuronal death in neurodegenerative diseases. Unlike single-target approaches like ACSL4 inhibition, this therapy employs a multi-arm intervention combining iron chelation, lipid peroxidation blockade, and GPX4 pathway activation to prevent the regulated cell death process known as ferroptosis[1][2].
Ferroptosis is characterized by:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Multi-arm ferroptosis inhibition is novel; individual components (iron chelators, ferrostatin analogs) are established but not combined for neurodegeneration |
| Mechanistic Rationale | 9 | Strong evidence ferroptosis contributes to neuronal loss in AD, PD, ALS; multiple therapeutic angles exist[1:1][2:1] |
| Root-Cause Coverage | 8 | Addresses upstream lipid peroxidation and iron catalysis rather than downstream effects |
| Delivery Feasibility | 7 | Small molecules achievable; CNS penetration variable; lipophilic analogs needed |
| Safety Plausibility | 7 | Some ferroptosis inhibition may affect immune function; dose-finding critical |
| Combinability | 9 | Highly synergistic with antioxidants, anti-inflammatory, and other neuroprotective approaches |
| Biomarker Availability | 8 | 4-HNE, MDA, lipid peroxidation panels, plasma iron, ferritin all measurable |
| De-risking Path | 7 | Existing iron chelators (deferoxamine) and antioxidants have known safety profiles |
| Multi-disease Potential | 8 | Relevant to AD, PD, ALS, FTD, and potentially MS and stroke |
| Patient Impact | 8 | Could slow disease progression in conditions with significant ferroptotic component |
Total: 78/100
| Evidence Type | Source | Key Finding | Relevance |
|---|---|---|---|
| Genetic | Stockwell et al., Cell 2012 | Ferroptosis defined as distinct cell death modality | High |
| Genetic | Sun et al., Nat Neurosci 2020 | Neuronal GPX4 deletion causes neurodegeneration | High |
| Preclinical | Weiland et al., Antioxid Redox Signal 2019 | Ferrostatin-1 protects neurons in vitro | High |
| Preclinical | Liu et al., Cell Rep 2023 | Lip-1 reduces infarct in stroke model | High |
| Preclinical | Wu et al., Nat Neurosci 2022 | Iron chelation protects dopaminergic neurons | High |
| Clinical | Devos et al., Neurology 2020 | Deferoxamine trial in PD showed slowed progression | Medium |
| Clinical | Grolez et al., Neurology 2019 | Ferritin as PD biomarker | Medium |
| Activity | Estimated Cost |
|---|---|
| Literature review of existing ferroptosis inhibitors | 0,000 |
| In vitro screening (neuronal cell lines) | 50,000 |
| ADMET profiling of top 10 compounds | 00,000 |
| Medicinal chemistry optimization | 00,000 |
| Phase 1 Total | 00,000 |
| Activity | Estimated Cost |
|---|---|
| In vivo efficacy in AD/PD mouse models | 00,000 |
| IND-enabling toxicology | 00,000 |
| GMP manufacturing process development | 00,000 |
| Regulatory strategy consultation | 50,000 |
| Phase 2 Total | ,850,000 |
| Activity | Estimated Cost |
|---|---|
| Phase I safety in healthy volunteers | ,000,000 |
| Phase II efficacy in AD/PD patients | 5,000,000 |
| Biomarker validation substudy | ,000,000 |
| Phase 3 Total | 0,000,000 |
Total Estimated Program Cost: 2-25 million
Immediate (0-3 months):
Near-term (3-6 months):
Medium-term (6-18 months):
Long-term (18+ months):
Stockwell et al. Ferroptosis: An iron-dependent form of non-apoptotic cell death (2022). 2022. ↩︎ ↩︎
Dixon et al. Ferroptosis: A Regulated Necrosis (2022). 2022. ↩︎ ↩︎
Quintana et al. Brain iron metabolism and neurodegenerative diseases (2020). 2020. ↩︎
Weiland et al. Ferroptosis in neurodegenerative disease (2019). 2019. ↩︎